Rossella: A Study to Evaluate the Safety PK Efficacy PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

  • STATUS
    Recruiting
  • End date
    Feb 3, 2025
  • participants needed
    22
  • sponsor
    Amicus Therapeutics
Updated on 3 November 2021

Summary

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-nave pediatric subjects with classic IOPD.

Details
Condition Glycogen Storage Disease Type II Infantile Onset
Treatment Cipaglucosidase alfa (ATB200), Miglustat (AT2221)
Clinical Study IdentifierNCT04808505
SponsorAmicus Therapeutics
Last Modified on3 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female subjects who are aged < 18 years at screening (For Cohort 1), 0 to <6 month (For Cohort 2 &3)
Confirmed diagnosis of classic IOPD
Subjects must have experienced a clinical decline based on their current approved rhGAA dose and frequency (For Cohort 1)

Exclusion Criteria

Subject received any investigational drug or any investigational biologic for Pompe disease within 30 days or 5 half-lives of the therapy or treatment, whichever is longer, before screening
Subject requires invasive ventilation (eg, tracheostomy) or respiratory assistance as defined in study protocol
Subject has received any gene therapy at any time
Subject who is CRIM-negative and has not received prophylactic immunomodulation (For Cohort 1)
Subject with high and sustained antibody titers as defined in study protocol (For Cohort 1)
Subject has any prior history of certain condition or any intercurrent illness as defined in study protocol
Subject has a hypersensitivity to any of the excipients in cipaglucosidase alfa or miglustat
Female subject is pregnant (or intends to get pregnant) or breastfeeding at screening (For Cohort 1)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note